Significant Ownership of Stonepine Capital Management, LLC
- Large-stake filing summary
-
- Recent SEC Schedule 13D/G filings for Stonepine Capital Management, LLC focus on large-stake beneficial ownership disclosures and amendments.
- Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
- Manager signature
- /s/ Jon M. Plexico - Managing Member
- Manager location
- Bend, OR
Large-stake snapshot
1 signal
Manager
Names, identifiers, and filing context for this profile.
2 identity fields
Follow Filing Activity
Follow Stonepine Capital Management, LLC with Pro and return when a new Schedule 13D/G filing changes the record on this page.
Pro alert delivery is coming soon and remains tied to source-backed filing changes rather than inferred market advice.
CIK context first
Continue from Stonepine Capital Management, LLC
Significant Ownership of Stonepine Capital Management, LLC
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| QNRX | Quoin Pharmaceuticals, Ltd. | Ordinary Shares | 11% | $47,201,973 | +$3,465,711 | 3,271,100 | +7.9% | Stonepine Capital Management, LLC | 29 Jan 2026 |
| CRIS | CURIS INC | Common Stock | 9.9% | $4,468,851 | 4,025,992 | Stonepine Capital Management, LLC | 17 Mar 2026 | ||
| INAB | IN8BIO, Inc. | Common Stock | 9.9% | $1,975,660 | 1,007,990 | Stonepine Capital Management, LLC | 19 Dec 2025 | ||
| AYTU | AYTU BIOPHARMA, INC | Common Stock | 9.9% | $1,975,217 | 906,063 | Stonepine Capital Management, LLC | 30 Jun 2025 | ||
| SINT | SINTX Technologies, Inc. | Common Stock | 9.9% | $1,474,629 | 619,592 | Stonepine Capital Management, LLC | 02 Jun 2026 | ||
| CNSP | CNS Pharmaceuticals, Inc. | Common Stock | 9.9% | $402,671 | +$279,627 | 159,790 | +227% | Stonepine Capital Management, LLC | 31 Mar 2026 |
| AZTR | Azitra, Inc. | Common Stock | 9.9% | $244,207 | 1,744,339 | Stonepine Capital Management, LLC | 16 Jun 2026 | ||
| CLRB | Cellectar Biosciences, Inc. | Common Stock | 9.9% | 863,277 | Stonepine Capital Management, LLC | 04 May 2026 | |||
| Eloxx Pharmaceuticals, Inc. | Common Stock | 9.9% | 403,228 | Stonepine Capital Management, LLC | 09 Jun 2026 | ||||
| OPTN | OptiNose, Inc. | Common Stock | 7.8% | $7,176,688 | +$1,819,909 | 788,647 | +34% | Stonepine Capital Management, LLC | 31 Mar 2025 |
| TELA | TELA Bio, Inc. | Common Stock | 6% | $2,211,913 | 2,353,099 | Stonepine Capital Management, LLC | 31 Dec 2024 | ||
| KTTA | Pasithea Therapeutics Corp. | Common Stock | 5.8% | $1,366,785 | 1,952,550 | Stonepine Capital Management, LLC | 17 Jun 2026 | ||
| CALC | CalciMedica, Inc. | Common Stock | 4.6% | $949,295 | -$170,674 | 628,672 | -15% | Stonepine Capital Management, LLC | 31 Mar 2025 |
| VSTM | Verastem, Inc. | Common Stock | 4.3% | $23,576,383 | -$1,441,948 | 2,670,032 | -5.8% | Stonepine Capital Management, LLC | 30 Sep 2025 |
| APRE | Aprea Therapeutics, Inc. | Common Stock | 4.3% | $418,978 | -$82,213 | 239,416 | -16% | Stonepine Capital Management, LLC | 31 Mar 2025 |
| INO | Inovio Pharmaceuticals, Inc. | Common Stock | 3.8% | $2,683,444 | -$900,721 | 1,434,997 | -25% | Stonepine Capital Management, LLC | 31 Mar 2025 |
| TENX | Tenax Therapeutics, Inc. | Common Stock | 3.7% | $14,588,992 | 975,200 | Stonepine Capital Management, LLC | 31 Mar 2026 | ||
| SRZN | Surrozen, Inc./DE | Common Stock | 3.6% | $6,531,368 | -$3,973,019 | 316,289 | -38% | Stonepine Capital Management, LLC | 31 Dec 2025 |
| KZR | Kezar Life Sciences, Inc. | Common Stock | 2.1% | $968,310 | -$1,370,578 | 156,179 | -59% | Stonepine Capital Management, LLC | 31 Dec 2025 |
| EDSA | Edesa Biotech, Inc. | Common Stock | 0.3% | $177,000 | -$3,914,951 | 30,000 | -96% | Stonepine Capital Management, LLC | 31 Mar 2026 |
Schedules 13D/G Reported by Stonepine Capital Management, LLC:
| Sym | Target | Class | Ownership | Change | Current shares | Change | Value | Reporting name | Form | Report period | Filing date |
|---|
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.